Welcome to our dedicated page for Betterlife Pharma SEC filings (Ticker: BETRF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BetterLife Pharma Inc. files as a foreign private issuer, and its SEC reports document current-event disclosures furnished on Form 6-K. The filings include news releases, material change reports, management’s discussion and analysis, financial statements, and CEO and CFO certifications.
BetterLife’s filings cover its biopharmaceutical development focus around BETR-001, financial reporting, liquidity and capital actions, governance updates, and public disclosure matters tied to its Canadian reporting framework and U.S. OTC-quoted security.
BetterLife Pharma Inc. files its annual Form 20‑F, highlighting a pre‑revenue biotech focused on mental health and antiviral drug candidates such as BETR‑001, MM‑001 and MM‑003. The company reported no revenue for the year ended January 31, 2026 and a net loss of $1,512,918, improved from $3,621,884 in 2025.
Cash was only $12,570 with a working capital deficiency of $6,459,206 and total assets of $219,903, against an accumulated deficit of $120,091,493. Management discloses material uncertainty that casts substantial doubt on the company’s ability to continue as a going concern and notes heavy dependence on additional equity or debt financing.
At January 31, 2026, BetterLife had 151,896,675 common shares outstanding, rising to 161,787,025 by May 29, 2026, and trades on the CSE and OTCQB as a penny stock, with associated volatility and liquidity risks. The filing also details past and current legal matters, including a Quebec lease judgment and concluded U.S. litigation, as well as significant outstanding executive compensation and equity incentive overhang.